Chen Wei, Wu Yubin, Hu Yubao
Department of Cardiology, Guilin People's Hospital, No. 12, Wenming Road, Guilin, 541002, Guangxi, China.
Diabetes Ther. 2018 Jun;9(3):1113-1124. doi: 10.1007/s13300-018-0425-1. Epub 2018 Apr 11.
At this time in 2018, with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) still on the rise, the post-percutaneous coronary interventional (PCI) outcomes observed in patients with diabetes mellitus who are on insulin therapy (ITDM) and those who do not require insulin (NITDM) are still controversial and require further investigation. Considering this idea to be of particular interest to the readers, as well as being an important issue in interventional cardiology, we aimed to systematically assess early (≤ 30 days), late (31-360 days) and very late (> 360 days) stent thrombosis in patients with ITDM and NITDM following drug-eluting stent (DES) implantation.
Well-known online databases (the Cochrane, EMBASE and MEDLINE databases and http://www.ClinicalTrials.gov ) were searched for relevant English publications based on ITDM and NITDM and stent thrombosis following PCI using specific terms. Early stent thrombosis, late stent thrombosis and very late stent thrombosis were the clinical outcomes. The main analysis was carried out using the latest version of the RevMan software (version 5.3) whereby odds ratios (OR), and 95% confidence intervals (CI) were generated.
A total of 8524 participants with T2DM (2273 participants were on insulin therapy and 6251 participants were not) were included. Results of this analysis showed early stent thrombosis to be significantly higher in patients with ITDM (OR 1.81, 95% CI 1.04-3.15; P = 0.04), whereas late and very late stent thromboses were not significantly different following PCI with DES in diabetic patients with versus without insulin therapy (OR 1.44, 95% CI 0.73-2.84, P = 0.30 and OR 0.80, 95% CI 0.33-1.92, P = 0.62, respectively). Late stent thromboses associated exclusively with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) were not significantly different in patients with ITDM and NITDM.
Following PCI with DES, early stent thrombosis was significantly higher in patients with ITDM. However, late and very late stent thromboses were not significantly different in patients with type 2 diabetes mellitus who were treated with or without insulin. Comparison with individual DES was not sufficiently powerful to reach a conclusion.
2018年的这个时候,2型糖尿病(T2DM)和冠状动脉疾病(CAD)仍在增加,接受胰岛素治疗的糖尿病患者(ITDM)和不需要胰岛素治疗的糖尿病患者(NITDM)经皮冠状动脉介入治疗(PCI)后的结果仍存在争议,需要进一步研究。考虑到这个问题对读者特别有吸引力,并且是介入心脏病学中的一个重要问题,我们旨在系统评估ITDM和NITDM患者在药物洗脱支架(DES)植入后早期(≤30天)、晚期(31 - 360天)和极晚期(>360天)的支架血栓形成情况。
使用特定术语在著名的在线数据库(Cochrane、EMBASE和MEDLINE数据库以及http://www.ClinicalTrials.gov)中搜索基于ITDM和NITDM以及PCI后支架血栓形成的相关英文出版物。早期支架血栓形成、晚期支架血栓形成和极晚期支架血栓形成为临床结局。主要分析使用RevMan软件的最新版本(5.3版)进行,由此生成比值比(OR)和95%置信区间(CI)。
共纳入8524例T2DM患者(2273例接受胰岛素治疗,6251例未接受胰岛素治疗)。该分析结果显示,ITDM患者早期支架血栓形成显著更高(OR 1.81,95% CI 1.04 - 3.15;P = 0.04),而在接受DES PCI治疗的糖尿病患者中,无论是否接受胰岛素治疗,晚期和极晚期支架血栓形成无显著差异(OR 1.44,95% CI 0.73 - 2.84,P = 0.30;OR 0.80,95% CI 0.33 - 1.92,P = 0.62)。仅与依维莫司洗脱支架(EES)和紫杉醇洗脱支架(PES)相关的晚期支架血栓形成在ITDM和NITDM患者中无显著差异。
DES PCI后,ITDM患者早期支架血栓形成显著更高。然而,在接受或未接受胰岛素治疗的2型糖尿病患者中,晚期和极晚期支架血栓形成无显著差异。与单个DES的比较力度不足,无法得出结论。